



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

ICD

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/465,429	12/21/1999	RICHARD C. BOUCHER JR.	5470-250	8856
20792	7590	08/02/2004	EXAMINER	
MYERS BIGEL SIBLEY & SAJOVEC			WANG, SHENGJUN	
PO BOX 37428				
RALEIGH, NC 27627			ART UNIT	PAPER NUMBER
			1617	

DATE MAILED: 08/02/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/465,429	BOUCHER, RICHARD C.
	Examiner Shengjun Wang	Art Unit 1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 3/31/04&4/13/04.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 22-24,31,32,37,44,49 and 51-53 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 22-24,31,32,37,44,49 and 51-53 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Receipt of applicants' amendments and remarks submitted March 31, 2004, and Declaration under 37 C.F.R. § 1.132 by Dr. Boucher, Jr. submitted April 13, 2004 is acknowledged.

Claim Rejections 35 U.S.C. 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 22-24,31,32,37,44,49,51-53 are rejected under 35 U.S.C. 103(a) as being unpatentable over Anderson (IDS, 5) in view of Boucher, Jr. et al. (U.S. Patent 5,876,700) and Jungherr et al. (U.S. Patent 5,837,266), and in further view of Robison et al. (IDS, October 3, 2003) and Eng et al. (IDS, October 3, 2003).

3. *Andersons teaches a method of increasing mucociliary clearance or inducing sputum comprising the step of causing a subject to inhale into subject's airway an osmolyte to increase the osmolarity of airway surface liquid. See, particularly, claims 12-21. The osmolyte may be any substance that is biologically compatible with the subject, preferably mineral salts, and more preferably sodium and potassium salt. See, column 3, lines 12-25, and claims 15 and 16. The technique, i.e., increasing mucociliary clearance and inducing sputum, is known to be useful for subject having cystic fibrosis. See, column 2, lines 14-33. Anderson further suggests the employment of aerosol administration for inhalation. See, particularly, col. 2, lines 14-33 in Anderson et al.*

Art Unit: 1617

4. Anderson does not teach expressly the employment of the method for treating cystic fibrosis, or administering a sodium channel blocker agent with an osmolyte for treating cystic fibrosis, or employ potassium sulfate as the osmolyte.

5. However, Boucher, Jr. et al. teach a method for hydrating mucous secretions in lungs, or for treating cystic fibrosis comprising administering to the patient by inhalation benzaminil or phenamil, the sodium channel blocker employed herein. See, particularly, the abstract, claims 1-5, 7-10, and 12-16. Jungherr et al. teaches that potassium sulfate is known to be biological compatible with human and is known to be useful in therapeutical composition as osmolyte. See, particularly, column 3, lines 26-33. Further, Eng teaches specifically the usefulness of osmolyte (as hypertonic solution) in mucociliary clearance and in providing treatment of cystic fibrosis. See particularly, the abstract, the introduction and discussion in Eng. Robinsons further teaches the usefulness of hypertonic saline in combination with amiloride, an sodium channel blocking agent See, particularly, the abstract, and the discussion.

Therefore, it would have been *prima facie* obvious to a person of ordinary skill in the art, at the time the claimed the invention was made, to treat a subject with cystic fibrosis by administering to the subject a combination of osmolyte, such as potassium sulfate and a sodium channel blocker, such as benzaminil or phenamil.

A person of ordinary skill in the art would have been motivated to treat a subject with cystic fibrosis by administering to the subject a combination of osmolyte, such as potassium sulfate and a sodium channel blocker, such as benzaminil or phenamil because it is *prima facie* obvious to combine two agents each of which is taught in the prior art to be useful for same purpose in order to form third composition that is to be used for very the same purpose; idea of

combining them flows logically from their having been individually taught in prior art; thus , the claimed invention which is drawn to a method for treating cystic fibrosis employing a combination of two agents, each of them is known to be useful for treating cystic fibrosis, sets forth *prima facie* obvious subject matter. See In re Kerkhoven, 205 USPQ 1069. The combination herein is obvious also because of the fact that hypertonic solution is known to provide benefit for treating cystic fibrosis when combined with other known anti-cystic fibrosis agent. The employment of potassium sulfate is seen to be a selection from amongst equally suitable potassium salts, particularly because potassium sulfate is known to be biological compatible to human and is known to be used as osmolyte in therapeutical composition. Ex parte Winters 11 USPQ 2nd 1387 (at 1388).

Response to the Arguments

Applicants' remarks and declaration submitted March 31, 2004 and April 13, 2004 have been fully considered, but are not persuasive for reasons discussed below.

Applicants allege the claimed invention are patentable based on an unexpected results shown by the declaration. Note the claims must be commensurate in the scope with any evidence of unexpected results. See MPEP 716.02 (d). In the instant case, the claims do not commensurate in the scope with the evidence of unexpected results shown in the declaration. Particularly, the declaration shown that co-application of a hypersonic potassium sulfate solution with a sodium channel blocker to a particular cell, i.e., cystic fibrosis bronchial epithelia, unexpectedly increase the penetration of the sodium channel blocker into the cells. However, as applicant admitted in the declaration, the airway epithelia in health and disease are poorly understood in the art. There

Art Unit: 1617

is no obvious reasons or expectation that the unexpected benefit would be extrapolated to any other salts or other airway epithelia.

Allowable Subject Matter

Based on the unexpected benefit presented in the declaration, following subject matter would be allowable:

A method of administering a sodium channel blocker to an airway surface of a subject in need thereof, comprising administering the sodium channel blocker in an effective therapeutic amount in a vehicle, said vehicle comprising potassium sulfate as an ionic osmolyte, said potassium sulfate included in an amount effective to increase the volume of liquid on the airway surface, wherein said subject is afflicted with cystic fibrosis.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (571)272-0632. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9302.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.


SHENGJUN WANG
PRIMARY EXAMINER
Shengjun Wang

July 28, 2004